Skip to main content

Helixgate

Skip to main content

Helixgate

Uncategorized

‘Zombie cells’ return from the dead — after a genome transplant

Published

on

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

STAT+: Michigan Supreme Court ruling allows probe into Lilly insulin pricing

A divided Michigan Supreme Court ruled on Friday that the state’s attorney general may investigate Eli Lilly over its pricing practices for insulin.

In its 4-to-3 decision, the court rejected a lower court decision that prevented Michigan Attorney General Dana Nesel from proceeding with a probe that began four years ago. At the time, Nessel cited state consumer protection laws, alleging the drug maker had artificially increased the price of its insulin medication.

Lilly was accused of charging “grossly” excessive prices for three different insulin products — Lispro, Humalog and Basaglar — that forced some patients to ration or forego  insulin, restrict their diets or buy less-effective alternatives. These practices led to “serious disability and even death in some patients,” the state wrote in court documents at the time.

Continue to STAT+ to read the full story…

Read More

Published

on

A divided Michigan Supreme Court ruled on Friday that the state’s attorney general may investigate Eli Lilly over its pricing practices for insulin.

In its 4-to-3 decision, the court rejected a lower court decision that prevented Michigan Attorney General Dana Nesel from proceeding with a probe that began four years ago. At the time, Nessel cited state consumer protection laws, alleging the drug maker had artificially increased the price of its insulin medication.

Lilly was accused of charging “grossly” excessive prices for three different insulin products — Lispro, Humalog and Basaglar — that forced some patients to ration or forego  insulin, restrict their diets or buy less-effective alternatives. These practices led to “serious disability and even death in some patients,” the state wrote in court documents at the time.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

De novo L-(+)-tartaric acid biosynthesis in multi-modular engineered yeasts

Published

on

Post Content

Continue Reading

Uncategorized

Capricor CEO won’t rule out legal action against FDA after negative adcomm

Capricor CEO won’t rule out legal action against FDA after negative adcomm

Published

on

After an FDA advisory committee voted 9-3 on Wednesday against recommending Capricor Therapeutics’ Duchenne muscular dystrophy cardiomyopathy drug for approval, stakeholders allege an “ulterior motive” and “biased intentions.”​ ​Read More

Continue Reading
Advertisement

Trending